About 7,560,000 results
Open links in new tab
Imfinzi is first and only immunotherapy to show survival benefit in ...
IMFINZI® (durvalumab) perioperative regimen reduced the risk of ...
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
FDA approves neoadjuvant/adjuvant durvalumab for resectable …
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in ... - AstraZeneca
IMFINZI® (durvalumab) is the first and only immunotherapy to …
IMFINZI® (durvalumab) demonstrated statistically significant and ...
Imfinzi Continuously Demonstrates Survival Benefit in Limited …
AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage …
FDA expands approval of Imfinzi to reduce the risk of non-small …